Reply

Journal of Allergy and Clinical Immunology

Volumn 115, Issue 2, 2005, Pages 430-431

  Oba, Yuji ^a   Salzman, Gary A ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB;

ASTHMA; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; LETTER; OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RESOURCE ALLOCATION;

EID: 85009106921     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.10.050     Document Type: Letter

References (4)

1. 1 Miller, T.P., Reeves, M.J., Lack of cost-effectiveness of omalizumab. J Allergy Clin Immunol 115 (2005), 429–430.
2. 2 Mellis, C.M., Peat, J.K., Woolcock, A.J., The cost of asthma: can it be reduced?. Pharmacoeconomics 3 (1993), 205–219.
3. 3 Zillich, A.J., Blumenschein, K., Johannesson, M., Freeman, P., Assessment of the relationship between measures of disease severity, quality of life, and willingness to pay in asthma. Pharmacoeconomics 20 (2002), 257–265.
4. 4 Siegel, J.E., Weinstein, M.C., Russell, L.B., Gold, M.R., Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276 (1996), 1339–1341.